Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552222 · ClinicalTrials.gov registry record · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,590
- Enrollment target
- 20
- Study locations
NCT05552222: Recruiting Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
NCT05552222 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 1,590 participants, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (193% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05552222, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,590 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Primary Outcome
PFS is defined as the duration from the date of randomization to either progressive disease or death, whichever comes first. Disease progression will be determined according to the International Myeloma Working Group (IMWG) response criteria.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Talquetamab
Study Locations (20)
California
- UCSF Fresno - Clovis
- City of Hope Duarte - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- Cancer and Blood Specialty Clinic - Los Alamitos
- Valkyrie Clinical Trials - Los Angeles
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- University of Arizona Cancer Center - Tucson
Connecticut
- University of Connecticut - Farmington
- Yale New Haven Hospital - New Haven
Florida
- AdventHealth Medical Group Blood & Marrow Transplant at Orlando - Orlando
- Cleveland Clinic Florida - Weston
Maryland
- Johns Hopkins University School of Medicine JHUSOM - Baltimore
- Center for Cancer and Blood Disorders - Bethesda
Delaware
- ChristianaCare Helen F Graham Cancer Center and Research Institute - Newark
Georgia
- City of Hope Cancer Center - Newnan
Illinois
- University Of Illinois Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,590 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2033-10-28 |
| Phase | Phase 3 |
What NCT05552222 shows while recruiting
NCT05552222 is an interventional study that assigns participants to a tested intervention. Its 1,590 participants enrollment target places it among the larger protocols in the corpus, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (193% higher).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Teclistamab is the first listed.
NCT05552222 names 20 study sites across 12 states, led by California, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05552222 about?
NCT05552222 is a clinical study titled "A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma". The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
What is the current status of trial NCT05552222?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,590 participants. The study started on 2022-10-25. Estimated completion is 2033-10-28.
What conditions does trial NCT05552222 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05552222?
The interventions under investigation include: Teclistamab (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Talquetamab (DRUG).
Who is sponsoring clinical trial NCT05552222?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05552222 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05552222's enrollment target sits among peer trials
1,590 16th of 438 higher than 423 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI